Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes

Cytokine

Volumn 34, Issue 3-4, 2006, Pages 219-223

  Yaturu, Subhashini ^a,b   Daberry, Robert P ^a   Rains, Justin ^b   Jain, Sushil ^b  

^a OVERTON BROOKS VA MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Adiponectin; Coronary artery disease; CRP; Insulin resistance; Resistin; TNF ; Type 2 diabetes

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; INSULIN; LIPID; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD CHEMISTRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745806251     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.05.005     Document Type: Article

References (42)

1. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 5 (2003) 1210-1214
2. Grundy S.M. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocr Metab 89 6 (2004) 2595-2600
3. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest 106 2 (2000) 171-176
4. Ridker P.M., and Morrow D.A. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 21 3 (2003) 315-325
5. Zhang J.L., Qin Y.W., Zheng X., Qiu J.L., and Zou D.J. Serum resistin level in essential hypertension patients with different glucose tolerance. Diabetic Med 20 10 (2003) 828-831
6. Heilbronn L.K., Rood J., Janderova L., Albu J.B., Kelley D.E., Ravussin E., et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocr Metab 89 4 (2004) 1844-1848
7. Banerjee R.R., and Lazar M.A. Resistin: molecular history and prognosis. J Mol Med 81 4 (2003) 218-226
8. Fujinami A., Obayashi H., Ohta K., Ichimura T., Nishimura M., Matsui H., et al. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 339 1-2 (2004) 57-63
9. Pfutzner A., Langenfeld M., Kunt T., Lobig M., and Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab Med 49 11-12 (2003) 571-576
10. Bajaj M., Suraamornkul S., Hardies L.J., Pratipanawatr T., and DeFronzo R.A. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28 6 (2004) 783-789
11. Rajala M.W., Obici S., Scherer P.E., and Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111 2 (2003) 225-230
12. McTernan P.G., Fisher F.M., valsamakis G., Chetty R., Harte A., McTernan C.L., et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocr Metab 88 12 (2003) 6098-6106
13. Krsek M., Silha J.V., Jezkova J., Hana V., Marek J., and Weiss V. Adipokine levels in Cushing's syndrome; elevated resistin levels in female patients with Cushing's syndrome. Clin Endocr (Oxf) 60 3 (2004) 350-357
14. Verma S., Li S.H., Wang C.H., Fedak P.W., Li R.K., Weisel R.D., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108 6 (2003) 736-740
15. Kawanami D., Maemura K., Takeda N., Harada T., Nojiri T., Imai Y., et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314 2 (2004) 415-419
16. Rajala M.W., Qi Y., Patel H.R., Takahashi N., Banerjee R., Pajvani U.B., et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 53 7 (2004) 1671-1679
17. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 1 (1999) 79-83
18. Asayama K., Hayashibe H., Dobashi K., Uchida N., Nakane T., Kodera K., et al. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res 11 9 (2003) 1072-1079
19. Matsubara M., Maruoka S., and Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocr Metab 87 6 (2002) 2764-2769
20. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscl Throm Vas 20 6 (2000) 1595-1599
21. Pellme F., Smith U., Funahashi T., Matsuzawa Y., Brekke H., Wiklund O., et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 52 5 (2003) 1182-1186
22. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocr Metab 86 5 (2001) 1930-1935
23. Engeli S., Feldpausch, Gorzelniak K., Hartwig F., Heintze U., Janke J., et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 52 4 (2003) 942-947
24. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 9 2 (2003) RA55-RA61
25. Yudkin J.S., Stehouwer C.D., Emeris J.J., and Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscl Throm Vas 19 4 (1999) 972-978
26. Fried S.K., Bunkin D.A., and Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocr Metab 83 3 (1998) 847-850
27. Hotamisligil G.S., Budavari A., Murray D., Spiegelman B.M., et al. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94 4 (1994) 1543-1549
28. Hotamisligil G.S., and Spiegelman B.M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43 11 (1994) 1271-1278
29. Sakuta H., Suzuki T., Yasuda H., and Ito T. Adiponectin levels and cardiovascular risk factors in Japanese men with type 2 diabetes. Endocr J 52 2 (2005) 241-244
30. Mohan V., Deepa R., Pradeepa R., Vimaleswaran K.S., Mohan A., Velmurugan K., et al. Association of low adiponectin levels with the metabolic syndrome-the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 54 4 (2005) 476-481
31. Shimada K., Miyauchi K., Mokuno H., Miyazaki T., Seki E., Watanabe Y., et al. Predictive value of the adipocyte-derived plasma protein adiponectin for restenosis after elective coronary stenting. Jpn Heart J 43 2 (2002) 85-91
32. Frystyk J., Tarnow L., Hansen T.K., Parving H.H., and Flyybjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48 9 (2005) 1911-1918
33. Hara K., Yamauchi T., and Kadowaki T. Adiponectin: an adipokine linking adipocytes and type 2 diabetes in humans. Curr Diab Rep 5 2 (2005) 136-140
34. Osei K., Gaillard T., and Schuster D. Plasma adiponectin levels in high risk African-Americans with normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes. Obes Res 13 1 (2005) 179-185
35. Rexrode K.M., Pradhan A., Manson J.E., Buring J.E., Ridker P.M., et al. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 13 10 (2003) 674-682
36. Al-Daghri N., Chetty R., McTernan P.G., Al-Rubean K., Attas O., Jones A.F., et al. Serum resistin is associated with c-reactive protein & ldl cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc Diabetol 4 1 (2005) 10
37. Kusminski C.M., McTernan P.G., and Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond) 109 3 (2005) 243-256
38. Lehrke M., Reilly M.P., Millington S.C., Iqbal N., Rader D.J., and Lazer M.A. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1 2 (2004) e45
39. Burnett M.S., Lee C.W., Kinnaird T.D., Stabile E., Durrani S., Dullum M.K., et al. The potential role of resistin in atherogenesis. Atherosclerosis 182 2 (2005) 241-248
40. Kougias P., Chai H., Lin P.H., Lumsden A.B., Yao Q., Chen C., et al. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 41 4 (2005) 691-698
41. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., Rader D.J., et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 7 (2005) 932-939
42. Steppan C.M., Wang J., Whiteman E.L., Birnbaum M.J., and Lazar M.A. Activation of SOCS-3 by resistin. Mol Cell Biol 25 4 (2005) 1569-1575